New England Journal of Medicine· 2014Q1

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan et al.

Short summary

Tumors with a high mutational load and specific neoantigens are associated with long-term clinical benefit from CTLA-4 blockade in melanoma patients.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

OncologyMedicine